Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Disease progression modelling reveals heterogeneity in trajectories of Lewy-type α-synuclein pathology ; volume:15 ; number:1 ; day:15 ; month:6 ; year:2024 ; pages:1-15 ; date:12.2024
Nature Communications ; 15, Heft 1 (15.6.2024), 1-15, 12.2024
- Creator
-
Mastenbroek, Sophie E.
Vogel, Jacob W.
Collij, Lyduine E.
Serrano, Geidy E.
Tremblay, Cécilia
Young, Alexandra L.
Arce, Richard A.
Shill, Holly A.
Driver-Dunckley, Erika D.
Mehta, Shyamal H.
Belden, Christine M.
Atri, Alireza
Choudhury, Parichita
Barkhof, Frederik
Adler, Charles H.
Ossenkoppele, Rik
Beach, Thomas G.
Hansson, Oskar
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-024-49402-x
- URN
-
urn:nbn:de:101:1-2408220850479.917179945191
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:50 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mastenbroek, Sophie E.
- Vogel, Jacob W.
- Collij, Lyduine E.
- Serrano, Geidy E.
- Tremblay, Cécilia
- Young, Alexandra L.
- Arce, Richard A.
- Shill, Holly A.
- Driver-Dunckley, Erika D.
- Mehta, Shyamal H.
- Belden, Christine M.
- Atri, Alireza
- Choudhury, Parichita
- Barkhof, Frederik
- Adler, Charles H.
- Ossenkoppele, Rik
- Beach, Thomas G.
- Hansson, Oskar
- SpringerLink (Online service)
Other Objects (12)
Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
LRP10 and α-synuclein transmission in Lewy body diseases
Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)
External validation of a 3-step falls prediction model in mild Parkinson’s disease
Towards a unified protocol for handling of CSF before β-amyloid measurements
Novel insights regarding the measurement properties of the SCOPA-AUT
Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
LRP10 and α-synuclein transmission in Lewy body diseases
Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)
External validation of a 3-step falls prediction model in mild Parkinson’s disease
Towards a unified protocol for handling of CSF before β-amyloid measurements
Novel insights regarding the measurement properties of the SCOPA-AUT
Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease
Effects of certain pre-analytical factors on the performance of plasma phospho-tau217
Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease
Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease
Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process
18F-AV-1451 in Parkinson’s Disease with and without dementia and in Dementia with Lewy Bodies
Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
LRP10 and α-synuclein transmission in Lewy body diseases
Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1–42)/Aβ(1–40)
External validation of a 3-step falls prediction model in mild Parkinson’s disease
Towards a unified protocol for handling of CSF before β-amyloid measurements